Bayliss, R. orcid.org/0000-0003-0604-2773, Sarnowska, E., Yeoh, S. et al. (1 more author) (2023) ALKing the flames of lung cancer immunosensitivity. Molecular Oncology, 17 (11). pp. 2218-2220. ISSN 1574-7891
Abstract
Immune checkpoint inhibitors (ICIs) are utilised in treating non-small cell lung cancer (NSCLC) by enhancing the immune response against cancer cells. However, they are not effective against cancers with certain genetic alterations. A recent study by Mota et al. focussed on understanding why ALK+ NSCLC cancers are immune cold and making them more receptive to ICIs using a vaccine-based approach. The study highlighted cell-specific differences in the presentation of immunogenic peptides and the location of tumours as factors in the poor immune response. Vaccines based on ALK peptides improved immune response, and when combined with ICIs, this led to a striking improvement in survival in a mouse model of ALK+ NSCLC.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
Keywords: | cancer vaccine; combination therapy; immunotherapy; lung cancer; tyrosine kinase inhibitors |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Biological Sciences (Leeds) > School of Molecular and Cellular Biology (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 30 Oct 2023 16:24 |
Last Modified: | 21 Nov 2023 11:33 |
Status: | Published |
Publisher: | Wiley |
Identification Number: | 10.1002/1878-0261.13533 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:204657 |